Boehringer Options RNA Splicing Derived Oncology Targets

Company Envisagenics / Boehringer Ingelheim Event Type Research Collaboration and Option Agreement Modality ADCs, T Cell Engagers, Multispecific Antibodies Asset SpliceCore-derived oncology targets Target Tumor-specific splice junction antigens (undisclosed) Disease Area Oncology Summary Envisagenics and Boehringer Ingelheim entered a multi year research and option agreement…